Thrombosis

Latest Features

Vascular Medicine Questions Remain Regarding VTE Recurrence in Older Adults

Questions Remain Regarding VTE Recurrence in Older Adults

Venous thromboembolism recurrence risk may not be any higher in older patients than in younger patients.

Latest News

Higher Risk for VTE With Oral vs Transdermal Hormone Replacement Therapy

Higher Risk for VTE With Oral vs Transdermal Hormone Replacement Therapy

Oral preparations of hormone replacement therapy for the treatment of menopausal symptoms are associated with a greater risk for VTE compared with transdermal formulations.

Rivaroxaban Supplemental New Drug Application Submitted to FDA for VTE Prophylaxis

Rivaroxaban Supplemental New Drug Application Submitted to FDA for VTE Prophylaxis

The sNDA submission was supported by Phase 3 data from the MAGELLAN and MARINER trials which assessed the use of rivaroxaban in preventing VTE in acute medically ill patients while hospitalized and immediately after discharge.

FDA Approves Generic Aminocaproic Acid Tablet

FDA Approves Generic Aminocaproic Acid Tablet

Aminocaprioc Acid Tablets are useful in enhancing hemostasis when fibrolysis contributes to bleeding.

Rivaroxaban in VTE: Lower Clinical Event Costs, But Higher Healthcare Costs

Rivaroxaban in VTE: Lower Clinical Event Costs, But Higher Healthcare Costs

Rivaroxaban was associated with lower clinical event costs but higher total healthcare costs compared with aspirin in patients with venous thromboembolism.

Baseline Thrombocytopenia Associated With Mortality Risk in VTE

Baseline Thrombocytopenia Associated With Mortality Risk in VTE

Patients with VTE with moderate to severe thrombocytopenia at baseline were associated with increased risk for major bleeding events and all-cause mortality.

VTE Increases Risk for Chronic Thromboembolic Pulmonary Hypertension

VTE Increases Risk for Chronic Thromboembolic Pulmonary Hypertension

A number of risk factors were associated with chronic thromboembolic pulmonary hypertension, including, age >70 years, female gender, and pulmonary embolism at first venous thromboembolism.

Pulmonary Embolism AEs Increase With DOAC Doses Against Manufacturer Recs

Pulmonary Embolism AEs Increase With DOAC Doses Against Manufacturer Recs

Patients treated for acute pulmonary embolism with direct oral anticoagulants at doses against manufacturer recommendations had a higher rate of major bleeding events.

FDA Approves Epoetin Alfa Biosimilar Retacrit

FDA Approves Epoetin Alfa Biosimilar Retacrit

The approval of Retacrit was based on a review of evidence that included human pharmacokinetic/pharmacodynamic data and clinical immunogenicity data which demonstrated a high degree of similarity between Retacrit and its reference product.

First Generic Alternative for Mephyton Now Available

First Generic Alternative for Mephyton Now Available

Amneal's generic product is available in a 5mg strength tablet supplied in 100-count bottles.

Independent Predictors of VTE Identified in Systemic Sclerosis

Independent Predictors of VTE Identified in Systemic Sclerosis

Researchers evaluated the prevalence, risk factors, and effect of venous thromboembolism on survival in systemic sclerosis.

Sign Up for Free e-Newsletters